Patients
Enanta applies its chemistry-driven approach and drug discovery capabilities to developing small molecule cures for viral infections impacting the highest at-risk patient populations. Long before the SARS-CoV-2 pandemic engulfed the world, Enanta always believed that the most profoundly beneficial impact to improve health is to address long-standing gaps in drug development R&D that have inadequately addressed the prevention and treatment of infectious diseases. Enanta’s commitment to ‘reach high’ on behalf of the most at-risk patients has been unyielding. Through our collaboration with AbbVie, we helped discover two cures for hepatitis C and today have novel, potential cures under development for infections of respiratory syncytial virus, SARS-CoV-2 and hepatitis B virus. At Enanta, we are building a leading treatment portfolio for viral respiratory infections. To learn more about participation in Enanta clinical trials, please see below.
Clinical Trials
Enanta is committed to the development of novel treatments for viral infections for patients with serious medical conditions. Enanta has active clinical trial programs in respiratory syncytial virus (RSV) and SARS-CoV-2 (COVID-19).
If you are interested in learning more about Enanta’s current and future clinical trials, please contact: patientinfo@enanta.com
Through clinical trials we are advancing novel therapeutics for significant respiratory infections.
Respiratory Syncytial Virus
Read More »
Therapeutic: EDP-938, in clinical development as a potential treatment for RSV infection
Trial Status: Actively recruiting
Trial Information: RSVPEDs is a Phase 2, randomized double-blind, placebo-controlled, dose-ranging study to evaluate EDP-938 in hospitalized or non-hospitalized infants and children aged 28 days to 36 months who test positive for RSV.
Approximately 90 patients aged 28 days to 36 months who test positive for RSV will be enrolled. To be included in the study, patients must have one or more signs of an acute respiratory illness (e.g. fever or symptoms of fever, cough, nasal congestion, runny nose, rapid breathing, shortness of breath, or wheezing) with onset 7 days or less before the time of signing the informed consent form.
The study has two parts, with the primary objective of Part 1 being to evaluate safety and pharmacokinetics. The primary objective of Part 2 is to evaluateantiviral activity as measured by the change in RSV shedding in nasopharyngeal swab samples determined using quantitative RT-PCR.
To visit the clinical trial website for RSVPEDs, click here
For more information, visit ClinicalTrials.gov Identifier: NCT04816721
Read More »
Therapeutic: EDP-938, in clinical development as a potential treatment for RSV infection
Trial Status: Actively recruiting
Trial Information: RSVTx is a Phase 2b randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of EDP-938 in adult hematopoietic cell transplant (HCT) recipients with acute RSV infection and symptoms of acute upper respiratory tract infection.
Approximately 200 adult subjects 18 Years to 75 years within 72 hours of symptom onset will be enrolled. Symptoms may include nasopharyngeal discharge, nasopharyngeal congestion, sneezing, sinus congestion, sore throat, hoarseness, earache, cough, shortness of breath, respiratory wheeze, or worsening of one of these symptoms if present chronically. To be included in the study, patients must have received an autologous or allogeneic HCT using any conditioning regimen and have an absolute lymphocyte count (ALC) less than 500 cells/ µL.
The primary objective of the study is theeffect of EDP-938 on development of lower respiratory tract complications in HCT subjects with acute RSV upper respiratory tract infection. The secondary objective of the study is to evaluate viral load and progression to respiratory failure, as well as pharmacokinetics and safety.
For more information, visit ClinicalTrials.gov Identifier: NCT04633187
Read More »
Therapeutic: EDP-938, in clinical development as a potential treatment for RSV infection
Trial Status: Actively recruiting
Trial Information: The Phase 2b, randomized, double-blind, placebo-controlled, multi-center, global study is designed to evaluate the effect of EDP-938 compared with placebo on the progression of RSV infection by assessment of clinical symptoms. Approximately 180 patients will be treated with 800 mg of EDP-938 or placebo for five days and evaluated for 28 days thereafter.
The study will include non-hospitalized adults with up to 72 hours of respiratory tract infection symptoms who test positive for RSV and negative for influenza virus and SARS-CoV-2. To be included in the study, the patient must have at least one of the following conditions that predispose them to complications after RSV infection: age ≥65 years, congestive heart failure (CHF), asthma or chronic obstructive pulmonary disease (COPD). The patient must have a new onset of any of the following symptom(s) or worsening of preexisting symptom(s) consistent with a respiratory tract infection no more than 72 hours prior to the administration of the first dose of study drug: feeling feverish, headache, neck pain, fatigue, loss of appetite, interrupted sleep, body aches, sore throat, nasal congestion, cough, cough with phlegm, wheezing, or short of breath. The patient must have at least two of the following symptoms, one of which must be reported as at least ‘moderate’ severity: cough, cough with phlegm, wheezing, or short of breath.
The primary endpoint of the study is time to resolution of RSV lower respiratory tract disease symptoms as assessed by the Respiratory Infection Intensity and Impact Questionnaire (RiiQ™) symptom scale through Day 33. Additional secondary endpoints include additional clinical efficacy measures and antiviral activity compared to placebo, pharmacokinetics, and safety of EDP-938.
For more information, visit ClinicalTrials.gov Identifier: NCT05568706
Read More »
Therapeutic: EDP-323, in clinical development as a potential treatment for RSV infection
Trial Status: Actively recruiting
Trial Information: This randomized, double-blind, sponsor-open, placebo-controlled study is assessing the safety, tolerability, and pharmacokinetics of orally administered single and multiple doses of EDP-323 in healthy adult subjects. Approximately 82 healthy subjects aged 18 to 65 years old will be enrolled. The first phase of the study assesses single ascending doses of EDP-323 or placebo in healthy subjects. A “fasted” and “fed” two-part cohort will also assess food effect. The second phase of the study assesses multiple ascending doses of EDP-323 or placebo for seven days in healthy subjects.
To be included in the study, subjects must have no clinically relevant history of illness or disease. Subjects cannot have infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening and infection with SARS-CoV-2 at the Day 1 visit. Pregnant or nursing females and current tobacco smokers cannot participate.
For more information, visit ClinicalTrials.gov Identifier: NCT05587478
SARS-CoV-2
Read More »
SPRINT (SARS‑Cov‑2 PRotease INhibitor Treatment)
Therapeutic: EDP-235, in development as a potential treatment for COVID-19
Trial Status: Enrollment Complete
Trial Information: SPRINT is a Phase 2 randomized, double-blind, placebo-controlled study enrolling approximately 200 non-hospitalized, symptomatic patients, aged 18 to 64, with mild to moderate COVID-19, who are not at increased risk for developing severe disease. To be included in the study patients must have tested positive for SARS-CoV-2 by PCR or rapid antigen test with a confirmed test within 24 hours before enrollment, had symptoms for five days or less and have not received a SARS-CoV-2 vaccine dose less than 90 days before enrollment and/or been infected with SARS-CoV-2 less than 90 days of enrollment.
Patients will receive EDP-235 orally at a dose of 200mg or 400mg or placebo once daily for five days. The primary objective of the study is to evaluate the safety and tolerability of EDP-235. Secondary objectives include the evaluation of virologic endpoints, clinical symptoms and outcomes, and pharmacokinetics
Expanded Access Policy
At Enanta, we are dedicated to discovering and developing safe and efficacious treatments for life-threatening viral infections. We understand the significant impact serious viral infections can have on patients and their caregivers. We are committed to making our therapies available to as many patients as possible, as safely and quickly as is feasible.
Our ongoing clinical trial programs, used to support regulatory approval, are the most effective way to access an Enanta investigational medication. Enanta encourages patients to speak with their treating physicians about participating in a clinical trial, when possible. You can find additional information about Enanta’s ongoing clinical trials on our website or by accessing www.clinicaltrials.gov
We understand that, in some cases, patients may not be eligible for clinical trials and do not have other treatment options. When enrollment into a clinical trial is not an option, and where all currently available treatment options have been exhausted, an investigational medicine may be provided prior to regulatory approval or commercial availability, under a provision referred to as “Expanded Access” by the U.S. Food and Drug Administration (FDA).
Read More »
Per FDA, Expanded Access may be appropriate when all of the following apply:
- Patient has a serious or immediately life-threatening disease or condition.
- There is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition.
- Patient enrollment in a clinical trial is not possible.
- Potential patient benefit justifies the potential risks of treatment.
- Providing the investigational medical product will not interfere with investigational trials that could support a medical product’s development or marketing approval for the treatment indication.
At this time, Enanta will make its investigational medicines available on an Expanded Access basis prior to regulatory approval, if the above conditions apply, as well as the following criteria are met:
- Adequate clinical data exist to support the appropriate dosing regimen of the investigational medicine and duration of treatment in the disease or condition.
- The company has an adequate supply of the investigational product to meet the needs of the expanded access program without impairing ongoing development, including ongoing and planned clinical trials.
- It should be logistically feasible for the company to provide the patient with the investigational drug.
- The requested use complies with applicable laws and regulations.
All requests for Expanded Access must come from a patient’s treating physician and will be evaluated by a multidisciplinary team and responded to on a case-by-case basis. Qualified and licensed physicians may make such requests at patientinfo@enanta.com. We target acknowledging receipt of requests as soon as possible and in most cases within two (2) business days. The requesting physician must agree to obtain appropriate regulatory and ethics committee approvals, and to comply with all other regulatory, safety, monitoring, and patient consent requirements.
Early access may be discontinued when approval of the drug is achieved in the patient’s country, subject to any legal or regulatory requirements. Similarly, expanded access may be discontinued if the benefit of treatment does not outweigh the risk or if any of the original required criteria are no longer met.
Enanta may revise this Expanded Access Policy at any time. The posting of this policy by Enanta shall not serve as a guarantee of access to any specific investigational medicine by any individual patient.
Patient Resources
Respiratory Syncytial Virus (RSV)
SARS-CoV-2 (COVID-19)
Hepatitis B Virus (HBV)
Human Metapneumovirus (hMPV)